For instance, the IMBRAVE-150 clinical trial demonstrated the superior efficacy of anti-VEGF and anti-PDL1 antibodies for the treatment of advanced stage HCC than that of Sorafenib48. This evidence concerns the gene VEGFA and hepatocellular carcinoma.